Search clinical trials for: LX201

Total 12 results

Innostellar Biotherapeutics Co.,Ltd

Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inherited Retinal Dystrophy

China
Lux Biosciences, Inc.

Completed

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

Noninfectious Uveitis

France, United States, Italy, Germany, Canada, United Kingdom, Czech Republic, Austria, Brazil
Shanghai General Hospital, Shanghai Jiao Tong University...

Not yet recruiting

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
Innostellar Biotherapeutics Co.,Ltd

Active, not recruiting

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Inherited Retinal Dystrophy Associated With RPE65 Mutations

China
Lux Biosciences, Inc.

Completed

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis (LUMINATE)

Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, United Kingdom, Canada, Germany, Austria, France, India
Lux Biosciences, Inc.

Completed

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis (LUMINATE)

Uveitis, Anterior | Panuveitis

United Kingdom, Canada, United States, Germany, Austria, France, India
Lux Biosciences, Inc.

Completed

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis (LUMINATE)

Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, United Kingdom, Canada, Germany, Austria, France, India
Rocket Pharmaceuticals Inc.
California Institute for Regenerative Medicine (CIRM)

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Leukocyte Adhesion Defect - Type I

Spain, United States, United Kingdom
Rocket Pharmaceuticals Inc.

Withdrawn

A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Leukocyte Adhesion Defect - Type I

Spain
Lux Biosciences, Inc.

Terminated

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Corneal Diseases | Cornea Transplant

United States, Germany
Lux Biosciences, Inc.

Terminated

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Corneal Transplantation | Corneal Graft Rejection

United States, Germany
Pacira Pharmaceuticals, Inc
Pacira Pharmaceuticals, Inc

Active, not recruiting

Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee

Osteoarthritis, Knee

United States

Search clinical trials for: LX201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations